These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21962879)

  • 1. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment.
    Liao CH; Chung SD; Kuo HC
    Urology; 2011 Dec; 78(6):1373-8. PubMed ID: 21962879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Hung SF; Chung SD; Kuo HC
    PLoS One; 2014; 9(1):e85588. PubMed ID: 24454896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms.
    Kwon H; Kang HC; Lee JH
    Urology; 2013 Jun; 81(6):1325-9. PubMed ID: 23602796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
    Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
    Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms.
    Ku JH; Ko DW; Cho JY; Oh SJ
    Urology; 2010 Jun; 75(6):1467-71. PubMed ID: 19962734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort.
    St Sauver JL; Sarma AV; Jacobson DJ; McGree ME; Lieber MM; Girman CJ; Nehra A; Jacobsen SJ
    Am J Epidemiol; 2009 Jun; 169(11):1281-90. PubMed ID: 19395697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
    Zhao S; Tang J; Shao S; Yan Y
    Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
    Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
    BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invited commentary: Lower urinary tract symptoms and inflammation--weighing the evidence.
    Freedland SJ; Aronson WJ
    Am J Epidemiol; 2009 Jun; 169(11):1291-3; discussion 1294-5. PubMed ID: 19395692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum C-reactive protein level is not associated with prostatic inflammation but with overactive detrusor in patients with benign prostatic hyperplasia.
    Inamura S; Ito H; Shinagawa T; Tsutsumiuchi M; Taga M; Tsuchiyama K; Kobayashi M; Yokoyama O
    Neurourol Urodyn; 2019 Aug; 38(6):1728-1736. PubMed ID: 31165507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
    El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K
    Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
    BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
    Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
    Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Hong SK; Lee ST; Jeong SJ; Byun SS; Hong YK; Park DS; Hong JY; Son JH; Kim C; Jang SH; Lee SE
    BJU Int; 2010 May; 105(10):1424-8. PubMed ID: 19874305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.